Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared to intravenous administration, enhancing patient outcomes.